Global Human Gene Sequencing Market Forecast 2026-2030 By Application, Technology, Workflow, Product, And Country AI And Precision Medicine Propel Market To $21.4 Billion By 2030

(MENAFN- GlobeNewsWire - Nasdaq) NGS Leads as Precision Medicine, Oncology and NIPT Adoption Accelerates, While Long-Read Sequencing, AI Bioinformatics and Pharma Partnerships Unlock Opportunities

Dublin, Oct. 09, 2026 (GLOBE NEWSWIRE) -- "Human Gene Sequencing Markets, Strategies & Trends. Forecasts by Application, by Technology, by Workflow, by Product, and by Country with Executive and Consultant Guides and Impact of Artificial Intelligence 2026 to 2030" has been added to ResearchAndMarkets.com's offering.

The global human gene sequencing market is projected to expand from more than USD 11.5 billion in 2025 to USD 21.4 billion by 2030, representing a compound annual growth rate of approximately 13.1%. Growth is being driven by increasing adoption across precision medicine, oncology, rare disease diagnostics, reproductive health screening, pharmacogenomics, infectious disease surveillance, pharmaceutical development, and biomedical research.

Since completion of the Human Genome Project in 2003, advances in sequencing accuracy, throughput, automation, and cost efficiency have accelerated the transition of human gene sequencing from specialized research into clinical practice. Healthcare providers, research institutions, pharmaceutical companies, and diagnostic laboratories are increasingly using genomic data to identify disease-associated variants, guide treatment selection, support drug development, and improve clinical decision-making.

Technology Evolution and Market Leadership

Next-generation sequencing represents the largest technology segment, supported by its capacity to analyze millions of DNA fragments simultaneously. NGS platforms enable whole genome sequencing (WGS), whole exome sequencing (WES), targeted gene panels, and transcriptome sequencing at a lower cost per base than first-generation sequencing methods such as Sanger sequencing.

Third-generation sequencing, including single-molecule and long-read sequencing technologies, is also gaining market attention. These platforms improve the detection of structural variants, repetitive sequences, genomic rearrangements, and other complex regions that can be difficult to resolve with short-read methods.

Sequencing workflows continue to benefit from advances in sample preparation, library construction, automated processing, cloud-based bioinformatics, and artificial intelligence. These improvements are increasing laboratory efficiency and strengthening genomic data interpretation capabilities.

Expanding Clinical and Research Applications

Oncology remains one of the most significant applications for human gene sequencing. Molecular profiling can identify actionable mutations associated with cancer development, progression, prognosis, and treatment response, supporting targeted therapy selection and clinical trial enrollment.

Rare disease diagnostics is another major growth area, as sequencing can identify pathogenic variants associated with inherited disorders. In reproductive health, non-invasive prenatal testing (NIPT) uses cell-free fetal DNA to detect chromosomal abnormalities, including trisomy 21. Pharmacogenomics is also expanding as healthcare providers use genetic information to support drug selection and dosing decisions.

Additional applications include infectious disease surveillance, pathogen monitoring, biomarker discovery, population genomics, evolutionary biology, and gene discovery. Large-scale genomic research programs are further increasing demand for high-throughput instruments, reagents, sequencing services, and bioinformatics platforms.

Key Human Gene Sequencing Market Drivers

• Growing adoption of precision medicine and personalized treatment strategies
• Increasing use of genomic profiling in oncology drug development
• Expansion of population genomics initiatives and preventive medicine programs
• Declining sequencing costs and improving platform accessibility
• Broader inclusion of genomic testing in clinical guidelines
• Advances in artificial intelligence, automation, and bioinformatics
• Rising demand for whole genome sequencing and targeted gene panels

Market Segmentation and Regional Outlook

By technology, next-generation sequencing holds the dominant market position because of its scalability, throughput, and broad clinical utility. WGS, WES, and targeted gene panels remain important sequencing formats. By application, oncology and NIPT account for leading market segments, supported by growing clinical adoption and continued innovation in genomic diagnostics.

North America represents the largest regional market due to its established research infrastructure, significant healthcare investment, active pharmaceutical industry, and high adoption of genomic medicine. Europe and Asia-Pacific are also recording strong growth as governments and research organizations invest in genomic databases, national sequencing programs, and precision medicine initiatives.

Competitive Landscape and Future Outlook

The competitive landscape includes sequencing instrument manufacturers, reagent suppliers, service providers, diagnostic laboratories, and bioinformatics companies. Market participants compete through sequencing accuracy, throughput, cost efficiency, workflow integration, regulatory expertise, and data analysis capabilities. Integrated solutions combining instruments, consumables, software, and interpretation services are becoming increasingly important.

Strategic partnerships between sequencing technology providers, pharmaceutical companies, healthcare systems, and research institutions are supporting biomarker discovery, clinical trials, and companion diagnostic development. Access to high-quality genomic databases and advanced interpretation platforms is also emerging as a key competitive differentiator.

The human gene sequencing market is expected to maintain strong long-term growth as whole genome sequencing becomes more accessible, long-read technologies mature, and genomic data becomes increasingly integrated into electronic health records. Continued innovation in artificial intelligence and bioinformatics is expected to improve variant interpretation, while expanding clinical applications will reinforce human gene sequencing as a foundational technology for precision medicine, biomedical research, and drug development.

Key Attributes:

Report Attribute	Details
No. of Pages	841
Forecast Period	2025 - 2030
Estimated Market Value (USD) in 2025	$11.55 Billion
Forecasted Market Value (USD) by 2030	$21.4 Billion
Compound Annual Growth Rate	13.1%
Regions Covered	Global

Companies Featured

• 10x Genomics, Inc.
• Abbott Laboratories
• AccuraGen Inc.
• Adaptive Biotechnologies
• Admera Health, LLC
• Advanced Biological Laboratories
• Agilent
• Akonni Biosystems
• Amoy Diagnostics Co., Ltd.
• Ancestry.com LLC
• Anchor Dx
• Arrayit Corporation
• ARUP Laboratories
• Astrid Bio
• Azenta
• BaseClear
• Baylor Miraca Genetics Laboratories
• Beckman Coulter Diagnostics (Danaher)
• Becton, Dickinson and Company
• BGI Genomics Co. Ltd
• Bioarray Genetics
• BioBam
• Biocept, Inc.
• Biodesix Inc.
• BioFluidica
• BioGenex
• Biolidics Ltd
• bioMerieux Diagnostics
• Bioneer Corporation
• Bio-Rad Laboratories, Inc.
• Bio-Techne
• Burning Rock
• C2i Genomics
• Cantata Bio
• CareDx
• Caris Molecular Diagnostics
• Celemics
• CellMax Life
• Centogene
• Cepheid (Danaher)
• Circulogene
• Clearbridge Biomedics
• Clinical Genomics
• Color Genomics
• Complete Genomics (MGI Tech)
• CosmosID
• Dante Labs
• Datar Cancer Genetics Limited
• Diasorin S.p.A.
• Easy DNA
• Element Biosciences
• Epic Sciences
• Epigenomics AG
• Eurofins Scientific
• Excellerate Bioscience
• Fabric Genomics
• Freenome
• FUJIFILM Wako Diagnostics
• Fujirebio
• Fulgent Genetics
• GE Global Research
• Gene by Gene, Ltd.
• Genedrive
• GeneDx Holdings
• GeneFirst Ltd.
• GeneFluidics
• Genetron Holdings
• Genewiz
• Genomics England
• Genomics Personalized Health (GPH)
• GenomOncology
• Genzyme Corporation
• Grifols
• Guardant Health
• Guardiome
• Helix
• Hologic
• HTG Molecular Diagnostics
• Human Longevity, Inc.
• iCellate
• Illumina
• Incell Dx
• Inivata
• Invitae Corporation
• Invivoscribe
• Karius
• Letsgetchecked
• Lucence Health
• Lunglife AI Inc
• Macrogen
• MDNA Life SCIENCES, Inc.
• MDx Health
• Medgenome
• Meridian Bioscience
• Mesa Laboratories, Inc.
• Metabiomics Corp
• miR Scientific
• NantHealth, Inc.
• Natera
• Nebula Genomics
• NeoGenomics
• New England Biolabs, Inc.
• NGeneBio
• Norgen Biotek Corp.
• Novogene
• Omega Bioservices
• Oncocyte
• OncoDNA
• OpGen
• Origene Technologies
• Oxford Nanopore Technologies
• Pacific Biosciences
• Panagene
• PathoQuest S.A.
• Personalis
• PGDx (Labcorp)
• Precipio
• PrecisionMed
• Predictive Oncology
• Promega
• Qiagen
• QuantuMDx
• Regeneron Pharmaceuticals
• Revvity
• Roche Diagnostics
• Roswell Biotechnologies
• Seegene
• SeLux Diagnostics
• Sequencing.com
• Siemens Healthineers
• simfo GmbH
• Singlera Genomics Inc.
• Singular Genomics
• SkylineDx
• Standard BioTools
• Sysmex
• Sysmex Inostics
• Tempus Labs, Inc.
• Thermo Fisher Scientific
• Ultima Genomics
• Unchained Labs
• Variantyx
• Vela Diagnostics
• VolitionRX
• Zymo Research Corp

For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN09102026004107003653ID1111782877